This finding aligns with earlier research showing increased levels of CD5 in AD, and supports the idea that dysregulated immune cell signaling—particularly involving CD6 and CD5—might play a role in the systemic nature of AD [69]. The gene discussed is CD6; the disease is Alzheimer disease.